DDInter299 DDInter1435
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Carfilzomib {u} (Compound) binds {v} (Gene) PSMB8
Carfilzomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Carfilzomib {u} (Compound) causes {v} (Side Effect) Headache
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Carfilzomib (Compound) resembles Ritonavir (Compound)
Carfilzomib (Compound) binds PSMB8 (Gene)
Carfilzomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Carfilzomib (Compound) causes Headache (Side Effect)
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Carfilzomib may lead to a major life threatening interaction when taken with Conestat alfa
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab